Time point | Collection regimen | Cyclophosphamide | Pegfilgrastim | G-CSF | ||||
---|---|---|---|---|---|---|---|---|
Mean value | 95% CI | Mean value | 95% CI | Mean value | 95% CI | Sig | ||
Before mobilization | Lym (× 109/L) | 1.81 | 1.27–2.34 | 1.48 | 1.17–1.80 | 1.43 | 1.20–1.66 | |
NK (× 109/L) | 0.20 | 0.15–0.26 | 0.18 | 0.12–0.23 | 0.22 | 0.15–0.28 | ||
Treg (× 106/L) | 8.53 | 4.1–12.9 | 10 | 5.28–14.6 | 6.86 | 4.24–9.48 | ||
Collection day | Lym (× 109/L) | 1.08 | 0.52–1.64 | 3 | 2.46–3.54 | 3.08 | 2.65–3.51 | |
NK (× 109/L) | 0.07 | 0.01–0.13 | 0.42 | 0.3–0.54 | 0.52 | 0.43–0.62 | ||
Treg (× 106/L) | 14.4 | 3.73–25.1 | 20.4 | 12.4–28.5 | 18.5 | 10.6–26.4 | .646 | |
Leukapheresis product | Lym(× 109/L) | 50.1 | 36–64.2 | 112 | 96.6–129 | 112 | 94.7–130 | |
NK (× 109/L) | 4.18 | 0.72–7.64 | 14.3 | 11.9–16.6 | 17.5 | 12.7–22.4 | ||
Treg (× 106/L) | 1030 | 392–1670 | 1030 | 400–1650 | 714 | 430–997 | 0.531 | |
D+15 | Lym (× 109/L) | 0.31 | 0.14–0.47 | 0.47 | 0.38–0.55 | 0.47 | 0.36–0.59 | 0.115 |
NK (× 109/L) | 0.05 | 0–0.85 | 0.10 | 0.04–0.16 | 0.10 | 0–0.34 | 0.357 | |
Treg (× 106/L) | 27.8 | 4.45–51.1 | 36.6 | 0–101 | 2 | 0–5.74 | 0.691 |
Characteristics | Total number of patients | G-CSF mobilization | Pegfilgrastim mobilization | Cyclophosphamide mobilization |
---|---|---|---|---|
Numbers | 48 | 20 | 19 | 9 |
Sex, M/F | 25 / 23 | 11 / 9 | 9 / 10 | 5 / 4 |
Median age (Range) years | 61 (35–71) | 60 (35–69) | 64 (51–71) | 59 (42–63) |
ISS stage 1/2/3 | 13/17/18 | 3/8/9 | 7/7/5 | 3/2/4 |
Median cycles of chemotherapy | 4 | 4 | 4 | 4 |
Patients with prior radiotherapy | 11 | 3 | 8 | 0 |
Response VGPR/PR/SD | 11/9/0 | 10/8/1 | 3/5/1 | |
Poor mobilizers | 3 | 1 | 2 | 0 |